In the current issue:
-
Can a negative PSMA PET/CT limit the indication for lymphadenectomy in patients with localized moderate- and high-risk prostate cancer?
Dianová Kristýna et al. -
Prediction of residual disease after chemotherapy in advanced NSGCT – does microRNA provide clinical benefits?
Pokrivčák Tomáš et al. -
Long term response to immunotherapy in a patient with low PD-L1 expression, high tumor mutational burden, and STK11 mutation
Kysela Michal et al.
Reviews
Klin Onkol 2026; 39(5): 320-324.
DOI: 10.48095/ccko2026320.
Keywords: prostate cancer – radical prostatectomy – Ga-68 PSMA PET/CT – pelvic lymphadenectomy – lymph node metastasis
Authors: Dianová Kristýna, Šámal Vladimír, Paldus Vít2026-10-15:Can a negative PSMA PET/CT limit the indication for lymphadenectomy in patients with localized moderate- and high-risk prostate cancer?
Keywords: prostate cancer – radical prostatectomy – Ga-68 PSMA PET/CT – pelvic lymphadenectomy – lymph node metastasis
Authors: Dianová Kristýna, Šámal Vladimír, Paldus Vít2026-10-15:Can a negative PSMA PET/CT limit the indication for lymphadenectomy in patients with localized moderate- and high-risk prostate cancer?
FLAURA2 – a step forward in first-line treatment of advanced EGFR-mutated non-small cell lung cancer
Klin Onkol 2026; 39(5): 325-330.
DOI: 10.48095/ccko2026325.
Keywords: carcinoma – non-small-cell lung cancer – osimertinib – drug therapy – combination – epidermal growth factor receptor (EGFR) – FLAURA2
Authors: Podhorec Ján, Poprach Alexandr2026-10-15:FLAURA2 – a step forward in first-line treatment of advanced EGFR-mutated non-small cell lung cancer
Keywords: carcinoma – non-small-cell lung cancer – osimertinib – drug therapy – combination – epidermal growth factor receptor (EGFR) – FLAURA2
Authors: Podhorec Ján, Poprach Alexandr2026-10-15:FLAURA2 – a step forward in first-line treatment of advanced EGFR-mutated non-small cell lung cancer
Original articles
Klin Onkol 2026; 39(5): 331-336.
DOI: 10.48095/ccko2026331.
Keywords: allogeneic transplantation – GvHD – quality of life – HRQoL
Authors: Pavúková Simona, Králik Roman, Dudová Dana , Payer Juraj, Drgoňa Ľuboš2026-10-15:Graft versus host disease as a marker for assessing quality of life in patients after allogeneic hematopoietic cell transplantation (results of a retrospective study)
Keywords: allogeneic transplantation – GvHD – quality of life – HRQoL
Authors: Pavúková Simona, Králik Roman, Dudová Dana , Payer Juraj, Drgoňa Ľuboš2026-10-15:Graft versus host disease as a marker for assessing quality of life in patients after allogeneic hematopoietic cell transplantation (results of a retrospective study)
Klin Onkol 2026; 39(5): 337-343.
DOI: 10.48095/ccko2026337.
Keywords: NSGCT – testicular germ cell tumors – microRNA – miR-371a-3p – biomarkers – retroperitoneal lymph node dissection – RPLND
Authors: Pokrivčák Tomáš, Hrstka Roman, Švancara Jan, Lakomý Radek, Poprach Alexandr, Staník Michal, Babánková Iva, Křístek Jan, Kiss Igor2026-10-15:Prediction of residual disease after chemotherapy in advanced NSGCT – does microRNA provide clinical benefits?
Keywords: NSGCT – testicular germ cell tumors – microRNA – miR-371a-3p – biomarkers – retroperitoneal lymph node dissection – RPLND
Authors: Pokrivčák Tomáš, Hrstka Roman, Švancara Jan, Lakomý Radek, Poprach Alexandr, Staník Michal, Babánková Iva, Křístek Jan, Kiss Igor2026-10-15:Prediction of residual disease after chemotherapy in advanced NSGCT – does microRNA provide clinical benefits?
Case report
Klin Onkol 2026; 39(5): 344-355.
DOI: 10.48095/ccko2026344.
Keywords: TEMPI syndrome – erythrocytosis – elevated erythropoietin – telangiectasia – perinephric fluid accumulation – perirenal lymphangiomatosis – monoclonal gammopathy – arteriovenous shunts – Waldenström’s macroglobulinemia
Authors: Adam Zdeněk, Vaníček Jiří, Řehák Zdeněk, Soboličová Sandra, Nehyba Svatopluk, Kubková Lenka, Kotašková Jana, Borský Marek, Felšӧci Marián, Čermák Aleš, Šimarová Eva, Šlampa Jakub, Leová Lan Ngoc, Boichuk Ivanna, Sandecká Viera, Štork Martin, Krejčí Marta, Pour Luděk2026-10-15:With the exception of perinephritic fluid collection, all symptoms of TEMPI syndrome resolved following treatment for Waldenström macroglobulinemia
Keywords: TEMPI syndrome – erythrocytosis – elevated erythropoietin – telangiectasia – perinephric fluid accumulation – perirenal lymphangiomatosis – monoclonal gammopathy – arteriovenous shunts – Waldenström’s macroglobulinemia
Authors: Adam Zdeněk, Vaníček Jiří, Řehák Zdeněk, Soboličová Sandra, Nehyba Svatopluk, Kubková Lenka, Kotašková Jana, Borský Marek, Felšӧci Marián, Čermák Aleš, Šimarová Eva, Šlampa Jakub, Leová Lan Ngoc, Boichuk Ivanna, Sandecká Viera, Štork Martin, Krejčí Marta, Pour Luděk2026-10-15:With the exception of perinephritic fluid collection, all symptoms of TEMPI syndrome resolved following treatment for Waldenström macroglobulinemia
Klin Onkol 2026; 39(5): 356-363.
DOI: 10.48095/ccko2026356.
Keywords: cholangiocarcinoma – IDH1 – ivosidenib – precision oncology – NGS
Authors: Eid Michal, Eidová Ľudmila2026-10-15:Ivosidenib in the treatment of IDH1-mutated cholangiocarcinoma – a review of current evidence and case report demonstrating durable disease control
Keywords: cholangiocarcinoma – IDH1 – ivosidenib – precision oncology – NGS
Authors: Eid Michal, Eidová Ľudmila2026-10-15:Ivosidenib in the treatment of IDH1-mutated cholangiocarcinoma – a review of current evidence and case report demonstrating durable disease control
Klin Onkol 2026; 39(5): 364-367.
DOI: 10.48095/ccko2026364.
Keywords: non-small cell lung cancer – immunotherapy – tumor mutational burden – STK11
Authors: Kysela Michal, Bílek Ondřej, Lordick Obermannová Radka, Grell Peter2026-10-15:Long term response to immunotherapy in a patient with low PD-L1 expression, high tumor mutational burden, and STK11 mutation
Keywords: non-small cell lung cancer – immunotherapy – tumor mutational burden – STK11
Authors: Kysela Michal, Bílek Ondřej, Lordick Obermannová Radka, Grell Peter2026-10-15:Long term response to immunotherapy in a patient with low PD-L1 expression, high tumor mutational burden, and STK11 mutation
Klin Onkol 2026; 39(5): 368-371.
DOI: 10.48095/ccko2026368.
Keywords: non-small cell lung cancer – RET fusion – targeted therapy – selpercatinib
Authors: Šuráňová Markéta, Bílek Ondřej, Neumann Aleš, Berkovcová Jitka, Kazda Tomáš, Kiss Igor2026-10-15:Detection of RET fusion in late-line treatment of NSCLC followed by long-term disease control with selpercatinib
Keywords: non-small cell lung cancer – RET fusion – targeted therapy – selpercatinib
Authors: Šuráňová Markéta, Bílek Ondřej, Neumann Aleš, Berkovcová Jitka, Kazda Tomáš, Kiss Igor2026-10-15:Detection of RET fusion in late-line treatment of NSCLC followed by long-term disease control with selpercatinib
Onkology in pictures
Klin Onkol 2026; 39(5): 372-377.
DOI: 10.48095/ccko2026372.
Authors: Hafiz Muhammad, Icksan Aziza G. , Andarini Sita Laksmi, Karim Nur M, Hasari Annisa Dian Hari, Syuaib Farhana Ibrahim, Widyawati Retno , Herdawat, Tati2026-10-15:Pregnancy-associated EGFR-mutant lung adenocarcinoma in a TB-endemic region – diagnostic bias and therapeutic barriers
Authors: Hafiz Muhammad, Icksan Aziza G. , Andarini Sita Laksmi, Karim Nur M, Hasari Annisa Dian Hari, Syuaib Farhana Ibrahim, Widyawati Retno , Herdawat, Tati2026-10-15:Pregnancy-associated EGFR-mutant lung adenocarcinoma in a TB-endemic region – diagnostic bias and therapeutic barriers
Letter to the Editor
Klin Onkol 2026; 39(5): 378.
Authors: Hafiz Muhammad2026-10-15:Diagnostic anchoring in metastatic adenocarcinoma – Was the turning point too late?
Authors: Hafiz Muhammad2026-10-15:Diagnostic anchoring in metastatic adenocarcinoma – Was the turning point too late?